Endocrinology Vol. 143, No. 1 254-262
Copyright © 2002 by The Endocrine Society
Gene Expression of Proprotein Convertases in Individual Rat Anterior Pituitary Cells and Their Regulation in Corticotrophs Mediated by Glucocorticoids
Weijia Dong and
Robert Day1
Département de Pharmacologie, Faculté de Médecine
and Institut de Pharmacologie de Sherbrooke, Université de
Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4
Address all correspondence and requests for reprints to: Robert Day, Ph.D., Department of Pharmacologie, Faculté de Médecine, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, Québec, Canada J1H 5N4. E-mail: rday{at}courrier.usherb.ca
 |
Abstract
|
|---|
The subtilisin-like proprotein convertases (SPCs) are a family of
serine proteinases that process secreted proteins at single or paired
basic residues. Each SPC has been localized in the rat anterior
pituitary, implying their importance in precursor processing in this
tissue. The cellular distribution of each SPC has not been established
in each hormone-producing cell type. We used double labeling in
situ hybridization histochemistry to examine the mRNA
distribution of five SPCs in relation to corticotrophs, thyrotrophs,
lactotrophs, gonadotrophs, and somatotrophs. Our data demonstrated that
SPC expression patterns were distinct, with each SPC expressed in more
than one cell type. We noted that overlapping SPC expressions were the
rule rather than the exception, suggesting potential SPC redundant
functions. We examined the effects of adrenalectomy on corticotroph SPC
expression. Most corticotrophs expressed SPC1, SPC3, and SPC4, but few
corticotrophs expressed SPC2 or SPC6. After adrenalectomy, we observed
increased mRNA levels for SPC1, SPC3, SPC4, and SPC6, but not for SPC2,
in POMC-positive anterior pituitary cells. These increased levels were
reversed by dexamethasone treatment. These data demonstrate the
plasticity of SPCs expression in corticotrophs. SPCs may be directly
involved in the mammalian stress response and may be important in
hypothalamic-pituitary-adrenal axis homeostasis.
 |
Introduction
|
|---|
THE ENDOCRINE ROLE of hormones produced by
the anterior pituitary gland is well established. Various peptides
identified in the central nervous system or peripheral tissues have
also been localized in the anterior pituitary (1, 2, 3, 4, 5).
These peptides together with the classical hormones function in an
endocrine or autocrine/paracrine manner to regulate the endocrine
system. ACTH as well as many other peptides are initially synthesized
as inactive precursors and are posttranslationally processed during
their intracellular transport to yield the final bioactive molecules.
An important step in this processing is the cleavage of precursors at
the C-terminal side of specific single or paired basic amino acids by a
family of subtilisin/kexin-like endoproteinases generally known as the
proprotein convertases (6). During the last several years,
seven distinct proprotein convertase genes have been identified in
mammalian species. Although each enzyme has been independently named by
their discoverers, a unified nomenclature has been proposed
(7), using the term subtilisin-like proprotein convertase
(SPC) which includes SPC1 (furin/PACE), SPC2 (PC2), SPC3 (PC1/PC3),
SPC4 (PACE4), SPC5 (PC4), SPC6 (PC5/PC6), and SPC7 (PC7/LPC/PC8).
Previous studies showed that SPC1 (8), SPC2 and SPC3
(9), SPC4 and SPC6 (10), and SPC7
(11) were all expressed in the anterior pituitary with
apparent distinct distribution patterns. However, the anterior
pituitary is highly heterogeneous, with five major hormone-producing
cell types, and it therefore becomes necessary to examine the cellular
distribution of each SPC to have a better understanding of
cell-specific functions. Colocalization studies of SPCs with hormone
markers should allow us to establish how SPCs are overlaid in their
anterior pituitary distribution. We have therefore characterized SPC1,
SPC2, SPC3, SPC4, and SPC6 mRNA expression in individual pituitary cell
populations by double label in situ hybridization. Rat GH,
PRL, POMC, FSH, and TSH cRNA probes were prepared and used as markers
of somatotrophs, lactotrophs, corticotrophs, gonadotrophs, and
thyrotrophs.
In previous studies we demonstrated that SPC3 mRNA levels were
selectively regulated by glucocorticoid feedback within parvocellular
neurons of the hypothalamic paraventricular nucleus, indicating the
involvement of enzyme regulation within the
hypothalamic-pituitary-adrenal (HPA) axis (12). As changes
in SPC expression levels could be an important mechanism in regulating
the biological output of the endocrine system through processing, it
was therefore of interest to study whether SPC gene expression is also
regulated in pituitary corticotrophs via glucocorticoids. Thus,
we examined SPC mRNA levels in corticotrophs under resting conditions
or subsequent to adrenalectomy (Adx), with or without dexamethasone
(Dex) replacement. The results demonstrated that glucocorticoid
feedback had an important influence on the detectable basal expression
of SPC1, SPC3, and SPC4. Furthermore, removal of glucocorticoid
feedback revealed an induction of SPC6, but not SPC2, mRNA expression
in corticotrophs. These data reinforce the idea of the role of SPCs in
the stress axis.
 |
Materials and Methods
|
|---|
Animals and tissue preparation
Animal experiments were performed following the recommendations
of the Canadian Council of Animal Care. Male Sprague Dawley rats
(250300 g) were used throughout this study. Twenty-three rats were
divided into four groups as follows: group I, sham Adx and vehicle
injection (n = 5); group II, sham Adx plus Dex treatment (n =
5); group III, Adx plus Dex treatment (n = 6); and group IV, Adx
plus vehicle injection (n = 7). Adx or sham Adx was performed
under methofane anesthesia. After 10 d, rats in each group
received either sc injections of 500 mg/kg Dex (Sigma, St.
Louis, MO) or vehicle injections twice daily for 4 d. Saline was
given to all animals as drinking water after the operation. The animals
were killed by decapitation. Whole pituitaries were rapidly removed and
frozen in isopentane precooled to -35 C. The pituitaries were stored
at -80 C and later sectioned on a cryostat at a thickness of 10 µm.
The frozen pituitary sections were thaw mounted on slides coated with
polylysine and stored at -80 C until further processing.
Probe synthesis
[35S]CTP- and
[35S]UTP-labeled cRNA probes were prepared for
SPC1, SPC2, SPC3, SPC4, and SPC6 from cDNA subclones in transcription
vectors. The rat (r) SPC1 cDNA consisted of 1231 nucleotides (nt)
equivalent to segment 823-2053 in human (h) SPC1 (13).
rSPC2 cDNA consisted of 425 nt equivalent to segment 15741998 in
mouse (m) SPC2 (14). rSPC3 cDNA consisted of 590 nt
equivalent to segment 18412430 in mSPC3 (15). rSPC4 cDNA
consisted of 534 nt equivalent to the segment 11531687 of hSPC4
(16); rSPC6 cDNA consisted of 837 nt, segment 10891925
(17). Nonradioactive cRNA probes were prepared using
digoxigenin (Dig)-11-UTP for detection of mRNAs of rGH, rTSH, rPOMC,
rPRL, and rFSH from cDNA subclones in transcription vectors as
previously described (18). Gonadotrophs were solely
examined using an FSH probe. The rFSH ß-subunit cDNA used (880 nts,
segment 1880) was provided by Dr. R. A. Maurer (Oregon Health
Sciences Center, Portland, OR) and has previously been described
(19). No LH probe was used to study gondotrophs, and
although the distributions of LH and FSH are known to be highly
similar, they are not exactly overlapping. The rPOMC cDNA (350 nt) was
a gift from Dr. J. Eberwine (University of Pennsylvania, Philadelphia,
PA) and corresponds to exon III of the POMC gene. The GH, TSH, and PRL
cDNAs were obtained by RT-PCR from extracted total RNA of rat anterior
pituitary as previously described (9, 20). The GH cDNA
(408 nt) corresponds to the region of nt 307714 of rat GH (GenBank
accession no. V01237). The TSH cDNA (301 nt) corresponds to the region
of nt 12312 of rat TSH ß-subunit (GenBank accession no. D00578).
The PRL cDNA (530 nt) corresponds to the region of nt 70679 of rat
PRL (GenBank accession no. V01249).
In situ hybridization histochemistry
The in situ hybridization protocols have been
described previously (18). The prehybridization treatment
includes fixation in 4% phosphate-buffered formaldehyde, proteinase K
treatment (0.1 µg/ml, 10 min at 37 C), and acetylation with acetic
anhydride (0.25%, vol/vol) in 0.1 M
triethanolamine. The cRNA probes were diluted to 33 x
103 dpm/µl and applied at 30 µl/slide.
Hybridization was carried out at 55 C for 16 h. The sections were
then treated with ribonuclease A (40 µg/ml) at 37 C for 45 min,
followed by a successive washes in 2, 1, and 0.5x SSC for 10 min each
at room temperature and in 0.1x SSC for 45 min at 60 C. Slides
hybridized with radioactively labeled cRNA probe alone were dehydrated
through graded ethanol and air-dried. Slides hybridized with both
radioactively and Dig-labeled cRNA probes were incubated with 2%
normal sheep serum and then with alkaline phosphatase-conjugated
anti-Dig antibody. This was followed by overnight incubation in the
dark in the chromagen solution consisting of 0.45 ml nitro blue
tetrazolium (75 mg/ml in 70% dimethylformamide) and 0.35 ml 5-
bromo-4-chloro-3-indolyl phosphate (50 mg/ml in dimethylformamide).
After stopping the reaction, slides were quickly dehydrated in graded
ethanol and air-dried. Slides were dipped in Ilford 5KD nuclear
emulsion (diluted 1:1 in water) and stored at 4 C for 26 wk.
Autoradiograms were developed in Kodak D19 (Rochester, NY)
for 2 min and fixed in 30% sodium thiosulfate for 4 min.
Analysis
Observation and analysis were carried out using a Carl Zeiss Axiophot microscope (New York, NY) equipped with a
Darklite Illuminator (Micro Video Instruments, Inc., Avon, MA).
Colocalization photographs were taken using double exposure settings.
The autoradiographic grains were first exposed under dark light
illumination, thus resulting in the white grain appearance. The second
exposure shows the Dig probe labeling revealed as dark
immunohistochemical staining. Quantitative studies were carried out at
x400 magnification by counting the grains on Dig-labeled cells. To
identify positive or negative labeling, nonspecific labeling in the
background and sense control sections were used as a reference. For the
percentage of labeled cells in Figs. 3
and 5
, each bar represents data
obtained by counting approximately 700800 cells from 3 animals. For
Table 1
and Fig. 5
, the average grain
number per cell was obtained by counting grains on approximately 135
cells from 3 animals. For Table 1
, values were adjusted to take into
account differences in the specific activity of each probe. Statistic
results are expressed as the mean ± SEM. Comparison
of mean values was performed by ANOVA, followed by Tukey-Kramer
multiple comparison test. Differences were considered significant at
P < 0.05. As a negative control for in situ
hybridization, radioactively labeled sense strand probes of the same
size and specific activity were applied instead of antisense strand
probes, and no positive labeling was encountered in the control
experiments.

View larger version (33K):
[in this window]
[in a new window]
|
Figure 3. Quantitative analysis of gene expression of SPCs
in individual anterior pituitary cell population by dual label
in situ hybridization histochemistry. Each
bar represents the percentage of cells that were
positively labeled by an SPC probe within an anterior pituitary cell
population identified using one of the hormone marker probes. As an
example, the black bars represent POMC-expressing cells.
Within this defined population, 85% of POMC-expressing corticotrophs
also expressed SPC1, SPC3, or SPC4, but less than 15% of this
population expressed SPC2 or SPC6. Each bar was obtained
by counting 700800 cells from sections of three different
animals.
|
|

View larger version (66K):
[in this window]
[in a new window]
|
Figure 5. Quantitative analysis of SPC mRNA in corticotrophs
(POMC-labeled cells) of anterior pituitary from Sham, Sham-Dex, Adx,
and Adx-Dex rats. Cell and grain counting was performed as described in
Fig. 1 and Table 1 . A dataset is shown for each SPCs including SPC1
(A), SPC3 (B), SPC4 (C), and SPC6 (D). The analysis was also carried
out for SPC2, but no significant changes were observed (data not
included). Statistically significant increases are indicated (*,
P < 0.05; **, P < 0.001),
where the comparison is made with the sham-treated group. Dex treatment
alone had no significant effect on the number of cells expressing an
SPC or on the level of SPC expression (determined by grain counting).
However, Dex treatment completely reversed the effects of Adx.
|
|
 |
Results
|
|---|
Anatomical distribution of SPC mRNAs in the normal rat
pituitary
The distribution of SPC1, SPC2, SPC3, SPC4, and SPC6 mRNAs in the
normal rat pituitary is shown in Fig. 1
and corresponds to our previously published data (9, 10, 11).
Each SPC has a distinct distribution pattern, with heterogeneous
expression levels within each of the pituitary lobes. All five SPCs
were expressed in the anterior lobe. Of all of the SPCs examined, SPC4
had the most widespread expression pattern within the anterior lobe
(Fig. 1D
), whereas, in contrast, SPC2 was expressed in a more select
population of anterior pituitary cells (Fig. 1B
). These images suggest
that different combinations of SPCs could be expressed in the distinct
hormone-producing cells of the anterior lobe, possibly with overlapping
patterns.

View larger version (138K):
[in this window]
[in a new window]
|
Figure 1. In situ hybridization
histochemistry of SPC mRNAs in rat pituitary. A, SPC1; B, SPC2; C,
SPC3; D, SPC4; E, SPC6; F, representative control section with sense
probe. AL, Anterior lobe; IL, intermediate lobe; NL, neural lobe.
Bar, 1 mm.
|
|
It is noted that within the more homogenous zone of the intermediate
lobe, SPC2 is abundantly expressed and colocalized with SPC1 and SPC3
mRNAs. However, the intermediate lobe melanotrophs expressed little if
any SPC4 or SPC6.
Colocalization of SPCs and hormone mRNAs in the normal rat anterior
pituitary
To examine the distribution of SPCs within individual anterior
lobe cell populations, we used a dual labeling in situ
hybridization methodology. Hormone-producing cells were detected using
Dig-labeled cRNA probes (i.e. POMC, GH, FSH, PRL, and TSH),
whereas SPC mRNAs were detected using radioactively labeled cRNA
probes. Dig-labeled cells were revealed as a dark-staining precipitate,
whereas radioactively labeled cells were detected by the presence of
silver grains (i.e. observed as white dots under dark field
microscopy). Representative examples of the complex labeling patterns
are shown in Fig. 2
, including SPC1
expression in lactotrophs (Fig. 2A
), SPC3 and SPC2 in thyrotrophs (Fig. 2
, B and C) and of SPC6 in gonadotrophs (Fig. 2F
). For the very widely
expressed SPC4 (Fig. 1D
), we also used this methodology to demonstrate
that gonadotrophs expressed less SPC4 than other anterior lobe cells
(Fig. 2E
).

View larger version (217K):
[in this window]
[in a new window]
|
Figure 2. Representative examples of dual labeling in
situ hybridization histochemistry of SPCs in individual
anterior pituitary cell populations. The labeled SPC mRNA is
represented by silver grains, which are revealed as white
dots. The labeled hormone probe is represented by
Dig-conjugated immunohistochemical precipitation, shown by dark
staining. Colocalization of SPC1 and PRL mRNA (A), SPC3 and TSH
mRNA (B), SPC2 and TSH (C), and a control section (D) labeled with
sense SPC2 and Dig labeling for TSH is shown. Very few grains are
observed, indicating the level of background. E, Colocalization of SPC4
and FSH mRNA. The expression levels of SPC4 were relatively lower in
FSH cells than in other cell types. F, Colocalization of SPC6 and FSH
mRNA. Bar, 50 µm.
|
|
Figure 3
and Table 1
summarize the
complex and heterogeneous distribution of SPC mRNAs in the anterior
lobe in a quantitative manner. For each anterior lobe hormone-
producing cell type we have determined the percentage of cells that
express a particular SPC (Fig. 3
). For example, using POMC as a marker
(Fig. 3
, black bars), we observed that a high percentage of
corticotrophs (>80%) expressed SPC1, SPC3, and SPC4, but few
corticotrophs (<15%) expressed SPC2 or SPC6. We also estimated the
relative abundance of each SPC within corticotrophs, as shown in Table 1
(i.e. POMC column). The data indicate that SPC4 was
clearly the most abundant SPC in corticotrophs. Although SPC2 and SPC3
mRNA levels were equally abundant in corticotrophs (Table 1
), it should
be remembered that SPC2 was expressed in very few corticotrophs
(i.e.
14%), whereas SPC3 was expressed in a large
majority of corticotrophs (i.e.
84%). For the
corticotroph cell population, the sum of these data lead us to conclude
that SPC4 and SPC3 are the most expressed convertases under normal
conditions.
A similar analysis of each of the other cell types has been carried
out. For GH-producing cells, we observed the expression of SPC1, SPC3,
and SPC4 in 8698% of all somatotrophs (Fig. 3
). When mRNA levels
were considered, SPC4 was the most abundant SPC in somatotrophs (Table 1
). It is important to note that although SPC2 mRNA levels were
slightly higher than those of SPC3 (Table 1
), only 6% of somatotrophs
express SPC2 compared with 86% for SPC3 (Fig. 3
).
High percentages of PRL-producing cell populations were labeled with
all five SPCs (Fig. 3
); however, the highest mRNA levels were observed
for SPC4, SPC2, and SPC3 (Table 1
). In the case of thyrotrophs, high
percentages of TSH-producing cells expressed SPC1, SPC2, SPC3, and
SPC4, but not SPC6 (Fig. 3
). High levels of SPC4, SPC2, and SPC3 mRNA
levels were also detected in thyrotrophs (Table 1
). It is noted that
thyrotrophs expressed the highest levels of SPC2 and SPC3 compared with
any other anterior pituitary cell type (see also Fig. 2
, B and C).
Finally, all of the examined SPCs were observed in gonadotrophs. High
percentages of FSH-producing cells expressed SPC1, SPC4, and SPC6
(between 7893%), whereas SPC2 and SPC3 were expressed in fewer cells
(3454%). In terms of relative mRNA abundance, SPC4 was once again
expressed at higher levels than the other SPCs in gonadotrophs (Table 1
). Of all of the hormone-producing pituitary cell types, gonadotrophs
were the major cell expressing SPC6 (Fig. 2F
). More specifically, SPC6
was principally expressed in almost all gonadotrophs (i.e.
nearly 90%) and in a subpopulation of lactotrophs (i.e.
50%; Fig. 3
).
Effects of Adx and Dex on SPC mRNA levels in anterior pituitary
corticotrophs
We next examined the regulation of each SPC within the
corticotroph anterior lobe cell population under the following four
conditions: 1) sham treatment, 2) sham and Dex treatment, 3) Adx
treatment, and 4) Adx followed by Dex treatment. As expected, after
Adx, POMC mRNA levels, were greatly increased in corticotrophs, whereas
administration of Dex completely reversed these changes (data not
shown). These observations confirmed the success of Adx treatment and
Dex replacement. Having confirmed that the treatments were effective,
we then focused our attention on the expression of SPCs within
corticotrophs of these same animals. Figure 4
shows examples of observed changes in
SPC mRNA levels within corticotrophs after Adx treatment. The most
important changes were seen for SPC3 (Fig. 4B
), SPC4 (Fig. 4D
), and
SPC6 (Fig. 4F
).

View larger version (156K):
[in this window]
[in a new window]
|
Figure 4. In situ hybridization
histochemistry showing the colocalization of SPCs mRNA and POMC mRNA in
corticotrophs after sham control treatment or Adx. The labeled SPC mRNA
is represented by silver grains, which are revealed as bright
dots. The labeled hormone (POMC) probe is represented by
Dig-conjugated immunohistochemical precipitation shown by the
dark brown staining. A, C, and E, Representative
pituitary sections from sham-treated rats; B, D, and F, sections from
Adx rats. All sections are labeled for corticotrophs using POMC as a
marker probe, whereas SPCs are in the following order: A and B, SPC3; C
and D, SPC4; and E and F, SPC6. Bar, 50 µm.
|
|
To quantitatively evaluate the effects of these treatments on SPC gene
expression within the corticotroph cell population, we determined both
the percentage of SPC-labeled cells as well as the SPC mRNA levels
using grain counting (Fig. 5
).
Significant changes were observed for SPC1, SPC3, SPC4, and SPC6. We
did not observe any significant differences for SPC2 under any of the
four treatment conditions (data not shown). The greatest increases
observed in the percentage of labeled corticotrophs were for SPC6 (Fig. 5D
). Under Adx conditions SPC6 labeled corticotrophs increased nearly
5-fold (from 12% to 60%). The greatest increase in mRNA levels was
observed for SPC4 (Fig. 5C
). Under Adx conditions SPC4 increased nearly
2-fold. In the case of SPC3 (Fig. 5B
) significant changes were observed
after Adx treatment, both in the percentage of labeled cells and in
mRNA levels. It was also noted that Dex treatment reversed each of the
changes observed after Adx treatment for SPC1, SPC3, SPC4, and SPC6. As
a final note, there were no observed changes in SPC expression after
ADX and Dex in the neurointermediate lobe.
 |
Discussion
|
|---|
Some of the most important current issues regarding the biological
function of the family of mammalian SPCs are in regard to their
substrate specificity and potential overlapping activities
(6). Various studies are currently investigating SPC
structure as well as cleavage specificity in cellular overexpression
systems (21, 22, 23) and in vitro assays
(24, 25, 26). However, an understanding of the precise
localization of these enzymes in vivo is also important to
determine whether overlapping cleavage specificity observed in
vitro could have any impact within the physiological content. The
first step to this understanding is to define the exact cellular
localization of each enzyme. This is a complex task in heterogeneous
tissues such as the pituitary. However, our dual labeling in
situ hybridization methodology has the advantage of defining
cellular localization while maintaining the integrity of the pituitary
tissue (18). Furthermore, a specific cell type can be
examined within the context of a regulatory paradigm such as that of
manipulating corticosteroids (12). In previous work we
have shown the gene expression of SPC1 (8), SPC2, SPC3
(9), SPC4, and SPC6 (10) in the pituitary. In
present work, we examined the colocalization of the mRNAs of these five
convertases with POMC, GH, PRL, TSH, and FSH mRNAs to identify the
distribution pattern in individual cellular populations in the anterior
pituitary. Interestingly, no individual pituitary cell population
expressed a single convertase, but at least three SPC mRNAs were
abundantly expressed in each cell type. Furthermore, we did not always
detect SPC expression in all cells (>90%) of a defined population
examined. A striking example was demonstrated for lactotrophs, which
were observed to express SPC1 and SPC4 in nearly all cells examined,
whereas only 5055% of lactotrophs expressed SPC2, SPC3, and SPC6.
This could be due to a technical difficulty, where the in
situ methodology could not detect very low levels of mRNA
expression. However, a more likely alternative explanation is that
subpopulations of individual pituitary cell types are regulating the
expression of the same SPC in a differential manner. The differential
expression of SPCs within lactotrophs suggests a different biological
output of peptides/hormones from at least two lactotroph
subpopulations.
A particular focus of our study was the POMC-expressing corticotroph
cell population. Previous studies have demonstrated the differential
cleavage specificity of SPC2 and SPC3 in the processing of the POMC
(22, 23), showing that ß- endorphin and
MSH are
generated by SPC2 and that ACTH and ß-lipotropin are generated by
SPC3. The general pattern of SPC2 and SPC3 expression fits with this
processing specificity, as SPC2 is mainly expressed in the homogeneous
intermediate lobe, but is not very highly expressed in the anterior
lobe. In contrast, SPC3 is highly expressed in the anterior lobe. In
the present study our data revealed a more complex situation within the
corticotroph cell population, showing that a majority of corticotrophs
(>80%) expressed SPC1, SPC3, and SPC4 mRNAs, whereas a minority of
corticotrophs (<20%) expressed SPC2 and SPC6. It was therefore
possible to conclude that convertases other than SPC3 could be involved
in the anterior lobe processing of POMC. A role for SPC2 in
corticotroph POMC processing was considered the most likely, because
SPC2 has clearly been shown to cleave POMC using a variety of assay
systems, including in vitro analysis (27),
cellular overexpression systems (22, 23, 28, 29, 30), and
knockout animals (31). The known anterior lobe processing
pattern for POMC includes the presence of ß- endorphin, along
with ß-lipotrophin, usually in approximately a 1:2 ratio
(32). The anterior lobe also produces minor amounts of
MSH-like material (33). The presence of SPC2 in a
subpopulation of corticotrophs is therefore a very likely explanation
for the presence of low levels of ß-endorphin and
MSH-like
peptides in the anterior lobe. Alternative explanations have been
proposed, including the secondary cleavage specificity of SPC3 for the
ß-endorphin site (22). However, only minute amounts of
ß-endorphin were generated using highly overexpressed SPC3,
suggesting that SPC3 is very ineffective in generating ß-endorphin.
Other SPCs expressed in corticotrophs could be potentially involved in
POMC processing. However, the role of SPC1 is thought to be limited,
because it cleaves precursors that enter the constitutive secretory
pathway (34), and thus its differential intracellular
localization may well preclude a physiological role in POMC processing.
Similarly, recent studies also seem to exclude SPC4 from a role in POMC
processing due its very distinct intracellular trafficking
(35). Although the exact intracellular compartment of SPC4
has not been identified, coexpression studies with POMC in
corticotroph-derived cell lines do not show any effect of SPC4 on POMC
processing (35). As for a potential role of SPC6 in POMC
processing, any conclusion would be premature, as the cleavage
specificity of SPC6 on POMC has not been reported. However, the
intracellular colocalization of SPC6 with POMC appears possible,
because studies have shown that the soluble form of this enzyme
(i.e. SPC6A) can be directed to secretory granules
(36), and this form is also present in the anterior
pituitary (37). The role of SPCs in corticotrophs is
certainly not limited to POMC processing, as other peptides, such as
gastrin-releasing peptide (1), galanin, and neuromedin U
(2), have been localized in corticotrophs.
The hormonal and pharmacological regulation of SPC gene expression has
been well documented. SPCs have been shown to be regulated by thyroid
status (9, 38), dopaminergic agonists and antagonists
(9), cAMP (39, 40, 41), TGFß (42),
seizure activity (43), retinoic acid (44),
and glucocorticoids (9, 12). Our studies have focused on
SPC gene expression in the HPA axis. It is well known that
glucocorticoids may exert their effects directly on the corticotrophs
via the classical type II GR or through their negative feedback effects
via the inhibition of hypothalamic CRH neurons. We have shown in
hypothalamic parvocellular CRH neurons the induction of SPC3 mRNA after
removal of endogenous glucocorticoids via adrenalectomy
(12). These data suggested an active role of SPCs in the
determination of the peptidergic output of hypothalamic neurons
implicated in the stress response and ultimately in the regulation of
pituitary corticotrophs. Using a similar paradigm, in the present study
we examined the effects of corticosteroid status on SPCs expressed in
the anterior lobe corticotrophs. Our present findings showed that SPC3
mRNA expression was up-regulated after adrenalectomy and that this
effect was reversed with Dex treatment. Interestingly, SPC3 was not the
only convertase to be up-regulated in corticotrophs. Similar results
were obtained for SPC1 and SPC4. Furthermore, a dramatic change was
observed for the corticotroph expression of SPC6, with an almost 2-fold
increase in mRNA levels appearing in 5- to 6-fold more corticotrophs
than under normal conditions. These results contrast with our previous
observation of SPC3 mRNA induction in CRH hypothalamic neurons
(12), as in those neurons we did not observe any changes
in SPC1, SPC2, SPC4, or SPC6 with the removal of glucocorticoids.
However, removal of glucocorticoids results in an increased drive from
the hypothalamic neurons, which could stimulate corticotrophs through
the actions of CRH and vasopressin. We also noted that treatment with
Dex alone did not significantly reduce basal expression levels of SPCs
in corticotrophs, although they clearly reversed the effects of Adx.
These data suggest that corticosteroids are not regulating SPC
expression directly at the pituitary level, but, rather, through
actions at CRH hypothalamic neurons.
Although individual components of the HPA axis have been extensively
examined, the molecular control mechanisms of the mammalian endocrine
response to stress are not yet well defined. Furthermore, the
functional relationship of many neuropeptides in the stress axis is not
understood. Certainly the plasticity of the pituitary corticotroph and
the ability to generate diversity through precursor processing could
have a significant impact on the functional response. The results of
the present study suggest that SPCs may be directly involved in the
mammalian stress response and may be important in HPA axis homeostasis.
Additional studies on the impact of stress and/or glucocorticoid levels
on SPC protein expression and cleavage activity will further address
the in vivo role of SPCs in HPA axis regulation.
 |
Acknowledgments
|
|---|
We thank Dr. R. A. Maurer (Oregon Health Sciences Center,
Portland, OR) for his generous gift of the rat FSH ß-subunit cDNA,
and Dr. J. Eberwine (University of Pennsylvania, Philadelphia, PA), who
kindly provided the rat POMC cDNA. We also thank Ms. Xue Wen Yuan for
excellent technical support.
 |
Footnotes
|
|---|
This work was supported by a grant from the Canadian Institutes of
Health Research (to R.D.).
1 Scholar (Chercheur Boursier Senior) of the Fonds de la Recherche en
Santé du Québec. 
Abbreviations: Adx, Adrenalectomy; Dex, dexamethasone; Dig,
digoxigenin; h, human; HPA, hypothalamic-pituitary-adrenal; m, mouse;
nt, nucleotides; r, rat; SPC, subtilisin-like proprotein
convertase.
Received June 8, 2001.
Accepted for publication September 10, 2001.
 |
References
|
|---|
-
Houben H, Denef C 1991 Evidence for the
presence of gastrin-releasing peptide immunoreactivity in rat anterior
pituitary corticotrophs and lactotrophs, AtT 20 cells and
GH3 cells. Failure to demonstrate participation
in local control of hormone release. Endocrinology 128:32083218[Abstract]
-
Cimini V, van Noorden S, Timson CM, Polak JM 1993 Modulation of galanin and neuromedin U-like immunoreactivity in the rat
corticotropes after alteration of endocrine status. Cell Tissue Res 272:137146[CrossRef][Medline]
-
Jones PM, Wither DJ, Ghatei MA, Bloom SR 1992 Evidence for neuromedin-B synthesis in the rat anterior pituitary
gland. Endocrinology 130:18291836[Abstract]
-
Roth KA, Krause JE 1990 Substance P is present in
a subset of thyrotrphs in the human pituitary. J Clin Endocrinol
Metab 71:10891095[Abstract]
-
Schwartz J 2000 Intercellular communication in the
anterior pituitary. Endocr Rev 5:488513
-
Bergeron F, Leduc R, Day R 2000 Subtilase-like
proprotein convertases: from molecular specificity to therapeutic
applications. J Mol Endocrinol 24:122[Abstract]
-
Chan SJ, Oliva Jr AA, LaMendola J, Grens A, Bode H,
Steiner DF 1992 Conservation of the prohormone convertase gene
family in metazoa analysis of cDNAs encoding a PC3-like protein from
hydra. Proc Natl Acad Sci USA 89:66786682[Abstract/Free Full Text]
-
Day R, Schäfer MK-H, Watson SJ, Chrétien M,
Seidah NG 1993 Region specific expression of furin mRNA in the rat
brain. Neurosci Lett 149:2730[CrossRef][Medline]
-
Day R, Schäfer MK-H, Watson SJ, Chrétien M,
Seidah NG 1992 Distribution and regulation of the prohormone
convertases PC1 and PC2 in the rat pituitary. Mol Endocrinol 6:485497[Abstract]
-
Dong W, Marcinkiewicz M, Vieau D, Chrétien M,
Seidah NG, Day R 1995 Distinct mRNA expression of the highly
homologous convertases PC5 and PACA4 in the rat brain and pituitary.
J Neurosci 15:17781796[Abstract]
-
Seidah NG, Hamelin J, Mamarbachi M, Dong W, Tardos H,
Mbikay M, Chretien M, Day R 1996 cDNA structure, tissue
distribution, and chromosomal localization of rat PC7, a novel
mammalian proprotein convertase. Proc Natl Acad Sci USA 93:338893[Abstract/Free Full Text]
-
Dong W, Seidel B, Marcinkiewicz M, Chrétien M,
Seidah NG, Day R 1997 cellular localization of the prohormone
convertases in the hypothalamic paraventricular and supraoptic nuclei:
selective regulation of PC1 in corticotrophin-releasing hormone
parvocellular neurons mediated by glucocorticoids. J Neurosci 17:563575[Abstract/Free Full Text]
-
Barr PJ, Mason OB, Landsberg KE, Wong PA, Kiefer MC,
Brake AJ 1991 cDNA and gene structure for a human subtilisin-like
protease with cleavage specificity for paired basic amino acid
residues. DNA Cell Biol 10:319328[Medline]
-
Seidah NG, Gaspar L, Mion P, Marcinkiewicz M Mbikay M,
Chrétien M 1990 cDNA sequence of two distinct pituitary
proteins homologous to Kex2 and furin gene products: tissue-specific
mRNAs encoding candidates for prohormone processing proteinases. DNA
Cell Biol 9:415424[Medline]
-
Seidah NG, Marcinkiewicz M, Benjannet S, Gaspar L,
Beaubien G, Mattei MG, Lazure C, Mbikay M, Chrétien M 1991 Cloning and primary sequence of a mouse candidate prohormone convertase
PC1 homologous to PC2, furin, and kex 2: distinct chromosomal
localization and messenger RNA distribution in brain and pituitary
compared to PC2. Mol Endocrinol 5:111122[CrossRef][Medline]
-
Kiefer MC, Tucker JE, Joh R, Landsberg KE, Saltman D,
Barr PJ 1991 Identification of a second human subtilisin-like
protease gene in the fes/fps region of chromosome 15. DNA
Cell Biol 10:757769[Medline]
-
Lusson J, Vieau D, Hamelin J, Day R, Chrétien M,
Seidah NG 1993 cDNA structure of the mouse and rat
subtilisin/kexin-like PC5: a candidate proprotein convertase expressed
in endocrine and nonendocrine cells. Proc Natl Acad Sci USA 90:66916695[Abstract/Free Full Text]
-
Schäfer MK-H and Day R 1994 In
situ hybridization techniques to study processing enzyme
expression at the cellular level. Methods Neurosci 23:1644
-
Maurer RA 1987 Molecular cloning and nucleotide
sequence analysis of complementary deoxyribonucleic acid for the
ß-subunit of rat follicle stimulating hormone. Mol Endocrinol 1:717723[CrossRef][Medline]
-
Day R, Dong W, Panetta R, Kraicer J, Greenwood MT, Patel
YC 1995 Expression of mRNA for somatostatin receptor (sstr) types
2 and 5 in individual rat pituitary cells: a double labeling in
situ hybridization analysis. Endocrinology 136:52325235[Abstract]
-
Seidah NG, Benjannet S, Hamelin J, Mamarbachi AM, Basak
A, Marcinkiewicz J, Mbikay M, Chretien M, Marcinkiewicz M 1999 The
subtilisin/kexin family of precursor convertases. Emphasis on PC1,
PC2/7B2, POMC and the novel enzyme SKI-1. Ann NY Acad Sci 885:5774[Medline]
-
Benjannet S, Rondeau N, Day R, Chrétien M, Seidah
NG 1991 PC1 and PC2 are proprotein convertases capable of cleaving
proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad
Sci USA 88:35643568[Abstract/Free Full Text]
-
Thomas L, Leduc R, Thorne BA, Smeekens SP, Steiner DF,
Thomas G 1991 Kex2-like endoproteases SPC3 and PC3 accurately
cleave a model prohormone in mammalian cells: evidence for a common
core of neuroendocrine processing enzymes. Proc Natl Acad Sci USA 88:52975230[Abstract/Free Full Text]
-
Basak A, Zhong M, Munzer JS, Chretien M, Seidah NG 2001 Implication of the proprotein convertases furin, PC5 and PC7 in
the cleavage of surface glycoproteins of Hong Kong, ebola and
respiratory syncytial viruses: a comparative analysis with fluorogenic
peptides. Biochem J 353:537545[CrossRef][Medline]
-
Day R, Lazure C, Basak A, Boudreault A, Limperis P, Dong
W, Lindberg I 1998 Prodynorphin processing by proprotein
convertase 2: cleavage at single basic residues and enhanced processing
in the presence of carboxypeptidase activity. J Biol Chem 273:829936[Abstract/Free Full Text]
-
Muller L, Lindberg I 1999 The cell biology of the
prohormone convertases PC1 and PC2. Prog Nucleic Acids Res Mol Biol 63:69108[Medline]
-
Hook VY, Moran K, Kannan R, Kohn A, Lively MO, Azaryan
A, Schiller M, Miller K 1997 High-level expression of the
prohormones proenkephalin, pro-neuropeptide Y, proopiomelanocortin, and
ß-protachykinin for in vitro prohormone processing. Protein Expr
Purif 1:8088
-
Zhou A, Mains RE 1994 Endoproteolytic processing of
proopiomelanocortin and prohormone convertases 1 and 2 in
neuroendocrine cells overexpressing prohormone convertases 1 or 2.
J Biol Chem 269:1744017447[Abstract/Free Full Text]
-
Zhou A, Bloomquist BT, Mains RE The prohormone
convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a
strict temporal order during proopiomelanocortin biosynthetic
processing. J Biol Chem 268:17631769
-
Friedman TC, Cool DR, Jayasvasti V, Louie D, Loh YP 1996 Processing of pro-opiomelanocortin in GH3 cells inhibition by
prohormone convertase 2 (PC2) antisense mRNA. Mol Cell Endocrinol 116:8996[CrossRef][Medline]
-
Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S,
Schambelan M, Steiner DF, Lindberg I, Leder P 1999 The
neuroendocrine protein 7B2 is required for peptide hormone processing
in vivo and provides a novel mechanism for pituitary Cushings
disease. Cell 96:689700[CrossRef][Medline]
-
Young EA, Przewlocki R, Patel P, Watson SJ, Akil H 1993 Altered ratios of ß-endorphin ß-lipotropin released from
anterior lobe corticotropes with increased secretory drive. I. Effects
of diminished glucocorticoid secretion. J Neuroendocrinol 5:115120[CrossRef][Medline]
-
Smith AI, Funder JW 1988 Proopiomelanocortin
processing in the pituitary, central nervous system and peripheral
tissues. Endocr Rev 1:159179
-
Molloy SS, Anderson ED, Jean F, Thomas G 1999 Bi-cycling the furin pathway: from TGN localization to pathogen
activation and embryogenesis. Trends Cell Biol 9:2835[CrossRef][Medline]
-
Mains RE, Berard CA, Denault JB, Zhou A, Johnson RC,
Leduc R 1997 PACE4 a subtilisin-like endoprotease with unique
properties. Biochem J 321:587593
-
De Bie I, Marcinkiewicz M, Malide D, Lazure C, Nakayama
K, Bendayan M, Seidah NG 1996 The isoforms of proprotein
convertase PC5 are sorted to different subcellular compartments. J
Cell Biol 135:12611275[Abstract/Free Full Text]
-
Seidah NG, Chretien M, Day R 1994 The family of
subtilisin/kexin like proprotein and pro-hormone convertases divergent
or shared functions. Biochimie 76:197209[Medline]
-
Johnson RC, Darlington DN, Hand TA, Bloomquist BT, Mains
RE 1994 PACE4: a subtilisin-like endoprotease prevalent in the
anterior pituitary and regulated by thyroid status. Endocrinology 135:11781185[Abstract]
-
Petit-Turcotte C, Paquin J 2000 Coordinate
regulation of neuroendocrine convertase PC2 and peptide 7B2 in P19
neurons. Peptides 21:365372[CrossRef][Medline]
-
Udupi V, Townsend Jr CM, Greeley Jr GH 1998 Stimulation of prohormone convertase-1 mRNA expression by second
messenger signaling systems. Biochem Biophys Res Commun 246:463465[CrossRef][Medline]
-
Mania-Farnell BL, Botros I, Day R, Davis TP 1996 Differential modulation of prohormone convertase mRNA by second
messenger activators in two cholecystokinin-producing cell lines.
Peptides 17:4754[CrossRef][Medline]
-
Blanchette F, Day R, Dong W, Laprise MH, Dubois CM 1997 TGFß1 regulates gene expression of its own converting enzyme
furin. J Clin Invest 99:19741983[Medline]
-
Marcinkiewicz M, Nagao T, Day R, Seidah NG, Chretien M,
Avoli M 1997 Pilocarpine-induced seizures are accompanied by a
transient elevation in the messenger RNA expression of the prohormone
convertase PC1 in rat hippocampus: comparison with nerve growth factor
and brain-derived neurotrophic factor expression. Neuroscience 76:425439
-
Jeannotte R, Paquin J, Petit-Turcotte C, Day R 1997 Convertase PC2 and the neuroendocrine polypeptide 7B2 are co-induced
and processed during neuronal differentiation of P19 embryonal
carcinoma cells. DNA Cell Biol 16:11751187[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
H. G. Sutton-Walsh, S. Whelly, and G. A. Cornwall
Differential Effects of GnRH and Androgens on Cres mRNA and Protein in Male Mouse Anterior Pituitary Gonadotropes
J Androl,
November 1, 2006;
27(6):
802 - 815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Bell, T. J. McDonald, and D. A. Myers
Proopiomelanocortin Processing in the Anterior Pituitary of the Ovine Fetus after Lesion of the Hypothalamic Paraventricular Nucleus
Endocrinology,
June 1, 2005;
146(6):
2665 - 2673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kato, K.-i. Kuwako, M. Suzuki, and S. Tanaka
Gene Expression Patterns of Pro-opiomelanocortin-processing Enzymes PC1 and PC2 During Postnatal Development of Rat Corticotrophs
J. Histochem. Cytochem.,
July 1, 2004;
52(7):
943 - 957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Cornwall, A. Cameron, I. Lindberg, D. M. Hardy, N. Cormier, and N. Hsia
The Cystatin-Related Epididymal Spermatogenic Protein Inhibits the Serine Protease Prohormone Convertase 2
Endocrinology,
March 1, 2003;
144(3):
901 - 908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Adatia, L. L. Baggio, Q. Xiao, D. J. Drucker, and P. L. Brubaker
Cellular Specificity of Proexendin-4 Processing in Mammalian Cells in Vitro and in Vivo
Endocrinology,
September 1, 2002;
143(9):
3464 - 3471.
[Abstract]
[Full Text]
[PDF]
|
 |
|